FGP
CPRX

Freestone Grove Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Freestone Grove Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.75M Buy
70,568
+39,654
+128% +$945K 0.01% 391
2025
Q4 		$722K Sell
30,914
-29,823
-49% -$664K 0.01% 511
2025
Q3 		$1.2M Buy
+60,737
New +$1.25M 0.01% 415

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Freestone Grove Partners's CPRX Position: Q1 2026 in Review

Freestone Grove Partners increased its Catalyst Pharmaceutical (CPRX) stake by 128% in Q1 2026, buying an estimated $945K and bringing the position to 70,568 shares worth $1.75M. The position accounts for 0.01% of the portfolio, ranked #391.

Freestone Grove Partners first reported a position in CPRX in Q3 2025 and has held it in 3 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Freestone Grove Partners held 70,568 shares of Catalyst Pharmaceutical worth $1.75M as of Q1 2026.
  • Freestone Grove Partners bought 39,654 Catalyst Pharmaceutical shares in Q1 2026, an estimated $945K.
  • Catalyst Pharmaceutical made up 0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #391 holding.
  • Freestone Grove Partners first reported a position in Catalyst Pharmaceutical in Q3 2025 and has held it in 3 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.